BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
SUBSCRIBE
BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
BullScope
No Result
View All Result
Home Market News

Moderna swings to profit as revenue growth accelerates to 29%, raises full-year outlook to 15-25%

Moe Alsumidaie by Moe Alsumidaie
November 9, 2026
in Market News
0
75
SHARES
1.3k
VIEWS
Share on XShare on LinkedInShare on Facebook

Moderna reported third-quarter revenue of $1.3 billion, up 29% from $1.0 billion a year earlier, and posted net income of $162 million compared to a net loss of $200 million in the same quarter of 2025. The company raised its full-year 2026 revenue growth guidance to 15-25%, up from a previous expectation of up to 10% growth, citing momentum from the U.S. FDA approval of mFLUSIVA (its fifth approved product globally) and positive Phase 3 data for the cancer therapy intismeran.

Third-quarter revenue of $1.3 billion broke down as $780 million in the U.S. and $533 million internationally, driven primarily by higher COVID vaccine sales in international markets under long-term government partnerships. Cost of sales rose 54% to $318 million, including $65 million in third-party royalties, reflecting higher product volume and manufacturing costs. Research and development expenses fell 27% to $583 million, mainly from lower clinical development costs following completion of certain late-stage infectious disease studies. Selling, general and administrative expenses increased 5% to $282 million. Diluted earnings per share were $0.38, compared to a loss per share of $0.51 in the third quarter of 2025, a $362 million year-over-year improvement.

For full-year 2026, Moderna now expects revenue growth of 15-25%, with approximately half from U.S. markets and half from international. The company raised its year-end cash and investments outlook to $8.1 billion to $8.3 billion, up from a prior range of $4.7 billion to $5.2 billion. This increase reflects $2.6 billion in net proceeds from a convertible notes offering completed in September, partially offset by a $950 million litigation settlement payment to GSK announced in October and operational cash use. Research and development expenses for the full year are now expected at approximately $2.7 billion, reduced from a prior forecast of $2.9 billion. Capital expenditures are expected at approximately $0.2 billion, improved from a prior range of $0.2 billion to $0.3 billion.

What it means

Moderna’s turnaround from a $200 million quarterly loss to $162 million in profit rests on two distinct drivers: operational leverage from higher vaccine sales, and a one-time financing event. The 29% revenue growth in the quarter is real, COVID vaccine deliveries under government partnerships in international markets are recurring, not promotional. The 27% decline in R&D spending, however, reflects a structural shift: the company has completed or wound down certain late-stage infectious disease studies, meaning this cost reduction may not persist if new programs require enrollment. The cost of sales rose faster (54%) than revenue (29%), suggesting manufacturing efficiency has not yet caught up to volume; if this gap widens, gross margin will compress despite higher sales.

BullScope TerminalWant the full evidence sheet behind pieces like this?The terminal runs the complete workup: Moderna, Inc. and 500+ other names, on the same official data.See the evidence engine →

The raised full-year guidance to 15-25% growth is material, but the document does not state what drove the upward revision, whether it reflects stronger-than-expected Q3 performance, new partnership agreements, or revised assumptions about vaccine demand. The $2.6 billion convertible financing inflates the year-end cash balance substantially and provides runway, but it also introduces future dilution if the stock price remains above the conversion threshold. The company maintains a global valuation allowance against most deferred tax assets, meaning it has not yet demonstrated sustained profitability to tax authorities.

The intismeran Phase 3 data in melanoma (58% reduction in recurrence or death risk after six months, in combination with Merck’s KEYTRUDA) is positive, but the document states only that Moderna and Merck are “working toward regulatory submissions”, no timeline is given. The norovirus vaccine program did not meet statistical success criteria in its Phase 3 interim analysis, and the company has deferred a decision on the methylmalonic acidemia program pending results from propionic acidemia, suggesting resource constraints or caution about pipeline breadth.

What to watch

The next material disclosure will be the propionic acidemia pivotal data readout, expected in 2026 according to the filing. That result will signal whether Moderna’s rare disease programs can generate revenue outside infectious disease and oncology, and whether the R&D cost reductions announced this quarter are sustainable or temporary. Regulatory decisions on intismeran and the flu/COVID combination vaccine (mCOFLU) in the U.S. and additional markets will also test whether the raised revenue guidance reflects durable product diversification or dependence on COVID vaccine cycles.

Source: the company’s 8-K filed 2026-11-06 with the SEC.

BullScope publishes impersonal research for a general audience. Nothing here is personalized investment advice, and nothing here is a recommendation to buy or sell any security. As of publication, neither BullScope nor its operator holds a position in any security, covered or otherwise; we do not trade at all, and we accept no compensation from any company we cover. When a conflict of interest exists, we do not publish: companies that compensate our operator in any capacity, or about which our operator could hold nonpublic information, are barred from coverage automatically, as described in the conflicts policy in our methodology. Figures come from company filings and public data through our published methodology; forecasts are conditional scenarios, not predictions and not promises. Markets carry risk, including loss of principal. Consider your own situation, or consult a licensed adviser, before acting on anything you read.

For the standing yardsticks on Moderna: the price tag, the filed record, and the four gauges, refreshed with each edition, see the BullScope Evidence Sheet: Moderna.

BullScope TerminalYou just read Moderna, Inc.’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →
Moe Alsumidaie

Moe Alsumidaie

Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.

Recommended For You

Zoetis narrows revenue outlook as U.S. companion animal sales slide, raises profit guidance on margin strength

by Moe Alsumidaie
November 6, 2026
0

Zoetis cut its full-year revenue forecast to $9.220 billion to $9.320 billion, representing organic operational decline of 2 percent to 1 p

Read moreDetails

Viatris Raises 2026 Guidance as Adjusted EBITDA Climbs 9 Percent Year to Date

by Moe Alsumidaie
November 6, 2026
0

Viatris raised the midpoints of its full-year 2026 financial guidance across all key metrics on the strength of nine-month adjusted EBITDA

Read moreDetails

Joby Aviation raises FY26 revenue outlook 15% as eIPP flights and defense contracts accelerate path to certification

by Moe Alsumidaie
November 5, 2026
0

Joby Aviation lifted its full-year 2026 revenue guidance by 15 percent and completed the first crewed eVTOL flights under the federal gover

Read moreDetails

Amgen’s revenue growth slows to 8% as biosimilar competition erodes legacy franchises

by Moe Alsumidaie
November 4, 2026
0

Amgen's third-quarter revenue rose 8% to $10.4 billion, a deceleration from the 10.0% full-year growth rate filed for fiscal 2025. The slow

Read moreDetails

Palantir’s U.S. commercial revenue overtakes government for the first time as quarterly sales accelerate to 96% growth

by Moe Alsumidaie
November 3, 2026
0

Palantir Technologies raised full-year revenue guidance to 91% growth after U.S. commercial revenue surpassed U.S. government revenue in th

Read moreDetails
Next Post

Zoetis: The Business Keeps Earning. The Price Keeps Falling. The Gap Between the Two Is Unusually Wide.

Please login to join discussion
BullScope
The Research Terminal
Run any stock through the BullScope evidence engine. Filings in, evidence out. Every number explains itself.
Open the Terminal
A BullScope product

Related News

Visa’s Margin Pause: What the Latest Quarter Actually Says

September 23, 2026

Goldman Sachs Is Earning Like It’s 2021. The Market Is Pricing It Like Something Better.

August 20, 2026

Hill or Cliff? The One Exchange That Defines Merck Right Now

August 5, 2026
BullScope

BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.

Prefer BullScope.ai on Google

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

No Result
View All Result
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

Not enough quota to unlock this post
Unlock left : 0
Are you sure want to cancel subscription?
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.